Nabriva Therapeutics Plc
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$30.64
-0.0
-1.09
$30.36M
39
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm's product, XENLETA (lefamulin injection, lefamulin tablets), is the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, required for bacterial growth, by binding with high affinity and specificity at molecular targets different from those of other available antibiotic classes, causing cell death.
emptyResult
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm's product, XENLETA (lefamulin injection, lefamulin tablets), is the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, required for bacterial growth, by binding with high affinity and specificity at molecular targets different from those of other available antibiotic classes, causing cell death.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.